Skip to content
    Clinical Trials

    Radiotherapy Plus Atezolizumab and Nab-Paclitaxel Is Feasible in TNBC Trial

    Ishiguro et alBreast Cancer

    Radiotherapy Plus Atezolizumab and Nab-Paclitaxel Is Feasible in TNBC Trial
    Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expressions, carrying a poor prognosis and limited therapeutic options. Prior studies have demonstrated the efficacy of combining immune checkpoint inhibitors (ICIs) with chemotherapy in advanced programmed death-ligand 1 (PD-L1)-positive TNBC, and radiotherapy (RT) may enhance therapeutic effects when combined with ICIs.
    The ongoing, single-arm, multicenter phase II IMRad-Br trial (jRCTs021210010) is evaluating the safety and feasibility of combining local RT with atezolizumab and nab-paclitaxel in patients with inoperable or recurrent PD-L1-positive TNBC. The treatment protocol administers atezolizumab at 840 mg on days 1 and 15 of a 28-day cycle, nab-paclitaxel at 100 mg/m² on days 1, 8, and 15, followed by local RT delivered at 30 Gy across five fractions.
    A safety run-in was conducted to assess protocol-defined prespecified adverse events of interest (PAEIs) in six evaluable patients. Among seven total enrolled patients, one PAEI occurred (grade 4 liver injury), which improved with treatment interruption and follow-up. Two additional serious adverse events occurred but were unrelated to the study treatment. With no unexpected toxicities observed, combination therapy was deemed feasible by an Independent Data Monitoring Committee. The trial remains ongoing to evaluate the safety and therapeutic potential of this ICI–RT combination strategy, with final analysis planned to determine whether the approach merits broader clinical adoption.

    Key Takeaways

    • Among seven enrolled patients in the safety run-in, one protocol-defined prespecified adverse event of interest occurred (a grade 4 liver injury), which improved with treatment interruption and follow-up.
    • Two additional serious adverse events were unrelated to study treatment, and with no unexpected toxicities observed, an Independent Data Monitoring Committee deemed the combination therapy feasible.